Particle.news
Download on the App Store
5 ARTICLES
·
last mo.

ASCO Conference Showcases Lifestyle-Adapted Immunotherapy and Promising Cancer Vaccines

Adjusting dosing schedules alongside early immunotherapy has improved treatment effectiveness; preliminary phase 1 personalized vaccines demonstrate promising responses against head and neck cancers.

Médecins, chercheurs et professionnels de santé de plus de 100 pays participent à la 61e réunion annuelle de l’ASCO. Cette réunion met en lumière les dernières découvertes dans tous les principaux domaines de l’oncologie.
Cyrille Vanlerberghe.
«De plus en plus d’études nous poussent à aller vers des traitements individualisés, en adaptant les doses ou le moment des injections», indique Steven Le Gouill, hématologue et directeur de l’ensemble hospitalier de l’Institut Curie
Les vaccins thérapeutiques ciblent entraînent le système immunitaire à combattre un adversaire qui est déjà là.

Overview

  • Studies at ASCO show that tailoring immunotherapy timing and dosing to patients’ daily routines can enhance efficacy and reduce adverse effects.
  • Trials indicate that administering immunotherapy earlier in treatment regimens improves patient outcomes with approved drugs now accessible in clinical practice.
  • Timothée Olivier cautioned that trial results may not reflect outcomes in real-world patients, especially those who are older or have comorbidities.
  • A phase 1 personalized therapeutic vaccine against head and neck cancers presented by Institut Curie researchers produced encouraging preliminary tumor responses.
  • Continued immunotherapy innovations over the past decade and a half have markedly boosted cancer patient survival, driving further research into personalized approaches.